Top Authors

• Most frequent coverage on XOMA

• 
  Centient Biotech Investor (10 followers)

  • Biotech Day in Review: Xoma Signs $230 Million Partnership with Takeda (Thu, Mar 1)
  • Biotech Stocks Review: Amphora Sells Oncology Program to Genentech (Wed, Jan 10)

  More by Centient Biotech Investor on XOMA »
• 
  Mike Havrilla (1908 followers)

  • Upcoming FDA Decisions and Clinical Trials: Prevacid Goes OTC, Swine Flu Test (Fri, May 15)
  • Navigating the Micro-Cap Biotech Minefield (Sun, Nov 23)

  More by Mike Havrilla on XOMA »
• 
  Michael Becker (159 followers)

  • Graft-Versus-Host Disease: Failures and Future Opportunities (Thu, Dec 10)
  • ADA Meeting 2009: Novel Diabetes Therapies Presented (Wed, Jun 24)

  More by Michael Becker on XOMA »

• Most followed authors on XOMA

• 
  Mike Havrilla (1908 followers)

  • Upcoming FDA Decisions and Clinical Trials: Prevacid Goes OTC, Swine Flu Test (Fri, May 15)
  • Navigating the Micro-Cap Biotech Minefield (Sun, Nov 23)

  More by Mike Havrilla on XOMA »
• 
  VFC's Stock House (1133 followers)

  • Readers Ask: Antares, GenVec, Xoma, (Sun, Sep 13)

  More by VFC's Stock House on XOMA »
• 
  Brett Steenbarger (885 followers)

  • Cash Is Not Yet King When it Comes to Market Performance (Wed, Dec 31)

  More by Brett Steenbarger on XOMA »

• Newest authors on XOMA

• 
  M. E. Garza (508 followers)

  • Friday's BioPlay: Xoma Ltd. (Fri, Jun 5)

  More by M. E. Garza on XOMA »
• 
  VFC's Stock House (1133 followers)

  • Readers Ask: Antares, GenVec, Xoma, (Sun, Sep 13)

  More by VFC's Stock House on XOMA »
• 
  Michael Becker (159 followers)

  • Graft-Versus-Host Disease: Failures and Future Opportunities (Thu, Dec 10)
  • ADA Meeting 2009: Novel Diabetes Therapies Presented (Wed, Jun 24)

  More by Michael Becker on XOMA »

• Most commented on XOMA

• 
  VFC's Stock House (1133 followers)

  • Readers Ask: Antares, GenVec, Xoma, (Sun, Sep 13)

  More by VFC's Stock House on XOMA »
• 
  Brett Steenbarger (885 followers)

  • Cash Is Not Yet King When it Comes to Market Performance (Wed, Dec 31)

  More by Brett Steenbarger on XOMA »
• 
  Douglas Cress (39 followers)

  • Race to Develop Bioterrorism Vaccine (Wed, Mar 11)

  More by Douglas Cress on XOMA »